Biogen Idec Inc. - Shareholder/Analyst Call Seeking Alpha Daclizumab is an antibody, again, being developed for multiple sclerosis, together with our partner, AbbVie. We had one large Phase II trial for that, that read out last year that had quite positive data. There's another Phase III trial that is fully ... |
